1.  INTRODUCTION

The Board of Directors of AHB wishes to announce that Tangming Shengshi Technology Precision Instrument (Suzhou) Co. Ltd. (formerly known as Tangming Shengshi Technology (Jiashan) Co. Ltd.) (“TMSS”) and Aemulus Corporation Sdn. Bhd. (“ACSB”), collectively referred to as the “Purchaser” and both wholly-owned subsidiaries of the Company, Zhejiang Revotronix Technology Co., Ltd., (浙江瑞测科技有限公司) (91330782MA2M0TRYX9), Shanghai Revotronix Hongjia Equipment Sales Co., Ltd., (上海瑞测泓嘉设备销售有限公司) (91310115MA1K4R5K8F), and Revotronix Technology Co., Ltd., (瑞测科技有限公司), collectively referred to as the “Revotronix”, had on 14 August 2025 come to an agreement to transfer the business of CMOS Image Sensors (CIS)  and light source (“Business”) from Revotronix to Purchaser (hereinafter referred to as “Transfer of Business”).

The Transfer of the Business encompasses the transfer of intellectual properties, technology and technology roadmap (“Technologies”), customer and vendor relationship, sales contracts, selected employees, inventories and fix assets previously owned by Revotronix at a total consideration of Renminbi Thirty Two Million Four Hundred Sixty Thousand (RMB32,460,000), equivalent to approximately Ringgit Malaysia Nineteen Million Ninety Two Thousand Nine Hundred (RM19,092,900) only (“Purchase Consideration”).

Revotronix is engaged in the sales, design and development of semiconductor and electronic equipment for CIS in China and signed a partnership agreement with TMSS in 2021.

The acquired Technologies, valued at RMB11 million, complements TMSS’s existing WSH5600 CIS test solution which Revotronix bought from TMSS since 2021. The Technologies reduce the reliance on third-party components, and secure direct access to key customers’ long-term potential businesses and product roadmaps. The inventories and fix assets, valued at RMB21.46 million, comprise of ready-to-deploy CIS tester components, R&D facilities and related materials.

A conditional customer order with a value of approximately RMB23 million is associated with the Transfer of Business.

The Transfer of Business is a strategic move which gives TMSS direct market accesses to one of the largest CIS maker globally, increasing our average selling price and orders.

2. FINANCIAL EFFECTS

The Transfer of Business is not expected to have material effects on the earnings, net assets and gearing of the Company for the financial year ending 30 September 2025.

3. RISK

The Transfer of Business is expected to contribute positively to our Company. However, there is no assurance that the anticipated benefits of the Transfer of Business will be realised or that the Company will be able to generate sufficient revenue and earnings therefrom to offset the associated Transfer of Business costs incurred. In mitigating such risk, the Company will actively monitor the execution of the agreement and to act swiftly to any deviation if it happens.

4. SOURCE OF FUNDING FOR THE PURCHASE CONSIDERATION FOR THE TRANSFER OF BUSINESS

The Purchase Consideration for the Transfer of Business will be funded by a combination of internally generated fund and bank borrowings. The exact proportion of the Purchase Consideration to be funded using internally generated fund and bank borrowings will be decided by the Company at a later stage, after taking into consideration its gearing level, interest costs as well as internal cash requirements for its business.

5. DIRECTORS’ AND MAJOR SHAREHOLDERS’ INTERESTS

None of the Directors, major shareholders and/or persons connected with them has any direct or indirect interest in the Transfer of Business.

6. DIRECTORS’ STATEMENT

The Board of Directors of AHB, having considered all aspect of the Transfer of Business, is of the opinion that the Transfer of Business is in the best interest of the Company.

7. APPROVALS REQUIRED 

The Transfer of Business is not subject to the approval of the shareholders of AHB.

This announcement is dated 14 August 2025.